Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.58 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.53 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.53 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.53 |
| ▸ | GABRP | O00591 | 1/20 | 0.53 |
| ▸ | GABRD | O14764 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10600091 | 0.97 | SLC22A6 (0.73) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL7005483 | 0.97 | SLC22A6 (0.73) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL23002867 | 0.94 | SLC22A6 (0.69) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL11616850 | 0.94 | TSHR (0.75) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL11750755 | 0.94 | TSHR (0.75) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL6413123 | 0.94 | TSHR (0.75) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL7834412 | 0.93 | LMNA (0.79) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL8761235 | 0.90 | TSHR (0.80) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL2349616 | 0.90 | TSHR (0.80) | SLC22A6LMNATSHRNFKB1PMP22 | |
| SCHEMBL25215828 | 0.90 | TSHR (0.80) | SLC22A6LMNATSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638388-A | Flame-retardant heat-conducting epoxy resin compound and preparation method thereof | 浙大宁波理工学院 | 2024-09-13 | — | — | CN | claimed |
| US-20240166679-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | LYGG CORPORATION | 2024-05-23 | — | — | US | claimed |
| EP-4301831-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | LYGG Corporation (US) | 2024-01-10 | — | — | EP | claimed |
| CN-117229136-A | Preparation method of azelaic acid | 北京旭阳科技有限公司 | 2023-12-15 | — | — | CN | claimed |
| CN-117222726-A | Use of ketoacids for stabilizing lignin in lignocellulosic biomass extraction processes | 理革公司 | 2023-12-12 | — | — | CN | claimed |
| WO-2022187716-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | LYGG CORPORATION (US) | 2022-09-09 | — | — | WO | claimed |
| US-8657430-B2 | Curable phase change inks containing crystalline polyesters | XEROX CORPORATION (US) | 2014-02-25 | — | — | US | claimed |
| US-8613506-B2 | — | — | 2013-12-24 | — | — | US | claimed |
| US-20120086761-A1 | CURABLE PHASE CHANGE INKS CONTAINING CRYSTALLINE POLYESTERS | XEROX CORPORATION (US) | 2012-04-12 | — | — | US | claimed |
| US-7732625-B2 | Colorant compounds | XEROX CORPORATION (US) | 2010-06-08 | — | — | US | claimed |
| US-7311767-B2 | Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens | XEROX CORPORATION (US) | 2007-12-25 | — | — | US | claimed |
| US-7033424-B2 | Phase change inks | XEROX CORPORATION (US) | 2006-04-25 | — | — | US | claimed |
| US-20060021546-A1 | Processes for preparing phase change inks | XEROX CORPORATION | 2006-02-02 | — | — | US | claimed |
| US-20060020141-A1 | Metallized dye | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-20060016369-A1 | PHASE CHANGE INKS | XEROX CORPORATION | 2006-01-26 | — | — | US | claimed |
| US-6989052-B1 | Phase change ink printing process | XEROX CORPORATION (US) | 2006-01-24 | — | — | US | claimed |
| US-20060004123-A1 | PHASE CHANGE INK PRINTING PROCESS | XEROX CORPORATION | 2006-01-05 | — | — | US | claimed |
| US-6946025-B2 | Process for preparing tetra-amide compounds | XEROX CORPORATION (US) | 2005-09-20 | — | — | US | claimed |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | XEROX CORPORATION | 2005-04-28 | — | — | US | claimed |
| US-4923708-A | ARYL, ALKYL OR ALKENYL DICARBOXYLIC ACID, CONFECTIONERY, COATINGS | NABISCO BRANDS, INC. (US) | 1990-05-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166679-A1 | USE OF KETOACIDS FOR LIGNIN STABILIZATION DURING EXTRACTION FROM LIGNOCELLULOSIC BIOMASS | KHK, LCT, HOGA1 | SLC22A6 3206/4885LMNA 848/4885TSHR 4839/4885 |
| US-20060020141-A1 | Metallized dye | CDYL, CDY1; CDY1B, CDYL2 | SLC22A6 1145/4885LMNA 1769/4885TSHR 2894/4885 |
| US-20050090690-A1 | Process for preparing tetra-amide compounds | TAF9, TAF5, TAF1 | SLC22A6 4580/4885LMNA 2024/4885TSHR 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.